VCANBIO(SH:600645) Zhi Tong Cai Jing·2025-09-09 10:23Core Viewpoint - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of VUM02 injection for the treatment of severe/critical pneumonia [1] Group 1 - VUM02 injection is an innovative drug developed by the company, derived from umbilical cord mesenchymal stem cells (UC-MSC) [1] - The drug is a cryopreserved cell preparation made from selected healthy newborn umbilical cord tissue, which undergoes in vitro separation, expansion, harvesting, and freezing [1] - The clinical trial aims to expand the indications for VUM02 injection to include the treatment of severe/critical pneumonia [1]